Valuation: Arvinas, Inc.

Market Cap 517M 463M 427M 386M 722M 49.19B 734M 5.09B 2.03B 25.74B 1.94B 1.9B 81.54B P/E 2026 *
-351x
P/E 2027 * -2.27x
Enterprise Value 65.81M 58.95M 54.38M 49.21M 92.02M 6.27B 93.51M 649M 259M 3.28B 247M 242M 10.39B EV / Sales 2026 *
0.22x
EV / Sales 2027 * 3.27x
Free-Float
79.97%
Yield 2026 *
-
Yield 2027 * -
1 day-0.25%
1 week+8.15%
Current month+2.07%
1 month+2.07%
3 months-4.88%
6 months-20.25%
Current year-33.43%
1 week 7.22
Extreme 7.22
8.03
1 month 6.74
Extreme 6.74
8.03
Current year 6.74
Extreme 6.74
14.51
1 year 6.74
Extreme 6.74
14.51
3 years 5.9
Extreme 5.9
53.08
5 years 5.9
Extreme 5.9
97.33
10 years 5.9
Extreme 5.9
108.46
Manager TitleAgeSince
Chief Executive Officer 47 12/02/2026
Director of Finance/CFO 56 24/06/2024
Chief Tech/Sci/R&D Officer 58 17/06/2024
Director TitleAgeSince
Chairman 66 15/06/2023
Director/Board Member 65 01/07/2018
Chairman 67 12/02/2026
Date Insider Type Main position Quantity % Market Cap. Importance
21/5/26 Sell

Chief Executive Officer

-2,209 0.0035%
11/5/26 Sell

Chief Financial Officer

-11,139 0.0174%
11/5/26 Sell

Chief Technology Officer

-11,108 0.0174%
Change 5-day change 1-year change 3-year change Capi.($)
-0.25%+8.15%-20.49%-47.65% 517M
-0.62%+0.50%+33.92%+60.07% 64.38B
+0.77%+3.63%+15.40%+85.32% 56.16B
+0.42%+1.90%+15.29%+106.68% 54.16B
-3.26%-5.00%+22.60%+49.80% 45.33B
+0.45%-1.27%+20.96%+99.79% 42.25B
-0.81%+0.76%+220.06%+926.81% 40.78B
+3.27%+47.96%+112.67%+96.48% 33.8B
+1.22%-1.39%+13.92%+46.95% 32.25B
-1.29%-1.72%+21.00%-6.85% 23.57B
Average -0.01%+4.48%+45.53%+141.74% 39.32B
Weighted average by Cap. -0.04%+3.64%+49.60%+160.98%

Financials

2026 *2027 *
Net sales 296M 265M 245M 221M 414M 28.2B 421M 2.92B 1.16B 14.76B 1.11B 1.09B 46.74B 64.19M 57.5M 53.05M 48M 89.76M 6.11B 91.21M 633M 252M 3.2B 241M 236M 10.13B
Net income -666K -597K -551K -498K -932K -63.46M -947K -6.57M -2.62M -33.21M -2.5M -2.45M -105M -248M -222M -205M -185M -347M -23.6B -352M -2.44B -975M -12.35B -930M -910M -39.12B
Net Debt -451M -404M -372M -337M -630M -42.92B -640M -4.44B -1.77B -22.46B -1.69B -1.66B -71.15B -307M -275M -254M -229M -429M -29.22B -436M -3.02B -1.21B -15.29B -1.15B -1.13B -48.43B
Projected Income Statement - Annual - Arvinas, Inc.
Logo Arvinas, Inc.
Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393, ARV-102, ARV-80, and ARV-027. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC to degrade BCL6, a transcriptional repressor and a regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.
Employees
246
Date Price Change Volume
31/10/26 USD 7.900 0.00% 209,400
29/10/26 USD 7.900 +3.95% 863,795
28/10/26 USD 7.600 +2.01% 891,608
27/10/26 USD 7.450 +1.92% 800,824
26/10/26 USD 7.310 +0.14% 724,861
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Arvinas, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
7.900USD
Average target price
13.93USD
Spread / Average Target
+76.31%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Arvinas, Inc.
  1. Stock Market
  2. Stocks
  3. ARVN Stock